Relmada Therapeutics, Inc. (RLMD) on Monday announced positive 12-month interim results from its Phase 2 trial evaluating NDV-01 for high-risk non-muscle invasive bladder cancer.
The bladder cancer treatment achieved a 76 percent complete response rate at 12 months, with an 80 percent response rate among patients with BCG-unresponsive disease.
The therapy also showed a favorable safety profile, with no progression to muscle-invasive disease and no patients requiring radical cystectomy. NDV-01 is a sustained-release intravesical formulation of gemcitabine and docetaxel designed for simplified in-office administration.
Based on the results, Relmada plans to advance NDV-01 into the Phase 3 RESCUE registrational program, expected to begin in mid-2026, targeting both BCG-unresponsive and intermediate-risk NMIBC patient groups.
RLMD is currently trading at $5.89 up $1.44 or 32.33 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.